Caribou Biosciences, Inc. Stock 12‑Month Price Target Raised to $11, Implies 869% Upside
Caribou Biosciences' average stock price target increased from $10 to $11 by 5 analysts, with a range of $1 to $32. This implies an 869% upside from the Oct. 6 closing price. The consensus rating remains 'Buy', with 3 Buys and 2 Holds.
How this was made
The 30-second read
Why it matters
Analyst consensus remains a Buy, but the target lift could spark short‑term buying pressure.
Market read
Analyst target raise provides a fresh data point for traders monitoring micro‑cap biotech stocks.
What to watch
No new clinical data; price target change reflects market hype rather than fundamentals.
Background
Caribou Biosciences is a CRISPR gene‑editing company listed on Nasdaq.
Ticker impact
Analysts raised Caribou Biosciences' average price target to $11, implying ~869% upside.
potential upside as investors price in higher expectations
Target raise is a fresh analyst action that could attract buying interest.
Market effects
May lift sentiment in the CRISPR/biotech sector.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
Target may be overly optimistic given early‑stage pipeline risks.
Key entities
- companyCaribou Biosciences, Inc.
CRISPR gene‑editing biotech.
